First trimester screening for aneuploidy: serum biochemical markers.

[1]  J. Canick,et al.  Second‐trimester maternal serum analyte levels associated with fetal trisomy 13 , 1999, Prenatal diagnosis.

[2]  H. Cuckle,et al.  Maternal serum screening for Down syndrome in the first trimester: experience from Belarus , 1999, Prenatal diagnosis.

[3]  A. Borrell,et al.  First‐trimester biochemical markers for Down syndrome , 1999, Prenatal diagnosis.

[4]  A. D'Agata,et al.  Maternal serum screening for trisomy 18 in the first trimester of pregnancy , 1998, Prenatal diagnosis.

[5]  E. Vanzi,et al.  First trimester screening for Down's syndrome using maternal serum PAPP‐A and free β=hCG in combination with fetal nuchal translucency thickness , 1998, British journal of obstetrics and gynaecology.

[6]  M. Sinosich,et al.  Prenatal screening in the first trimester of pregnancy , 1998, Prenatal diagnosis.

[7]  J. Haddow,et al.  Screening of maternal serum for fetal Down's syndrome in the first trimester. , 1998, The New England journal of medicine.

[8]  J. Haddow,et al.  hCG and the free β‐subunit as screening tests for Down syndrome , 1998 .

[9]  L. Kornman,et al.  Maternal serum levels of free β‐hCG and PAPP‐A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery , 1998, Prenatal diagnosis.

[10]  D. Krantz,et al.  First‐trimester screening for fetal aneuploidy: biochemistry and nuchal translucency , 1997, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[11]  B. No̸rgaard-Pedersen,et al.  Double-monoclonal immunofluorometric assays for pregnancy-associated plasma protein A/proeosinophil major basic protein (PAPP-A/proMBP) complex in first-trimester maternal serum screening for Down syndrome. , 1997, Clinical chemistry.

[12]  L. Kornman,et al.  Women's opinions and the implications of first‐ versus second‐trimester screening for fetal Down's syndrome , 1997, Prenatal diagnosis.

[13]  J. Connor,et al.  Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimesters , 1997, British journal of obstetrics and gynaecology.

[14]  J. Moutquin,et al.  Screening for Down syndrome during first trimester: a prospective study using free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. , 1997, Clinical biochemistry.

[15]  J. Haddow,et al.  Maternal serum screening for Down syndrome in the United States: a 1995 survey. , 1997, American journal of obstetrics and gynecology.

[16]  K. Spencer,et al.  FREE BETA hCG SCREENING OF HYDROPIC AND NON‐HYDROPIC TURNER SYNDROME PREGNANCIES , 1996, Prenatal diagnosis.

[17]  N. Wald,et al.  Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy , 1996, British journal of obstetrics and gynaecology.

[18]  D. Krantz,et al.  First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. , 1996, American journal of obstetrics and gynecology.

[19]  N. Wald,et al.  PRENATAL SCREENING FOR DOWN'S SYNDROME USING INHIBIN‐A AS A SERUM MARKER , 1996, Prenatal diagnosis.

[20]  K. Nicolaides,et al.  Gene expression of human pregnancy-associated plasma protein-A in placenta from trisomic pregnancies. , 1996, Placenta.

[21]  A. Hackshaw,et al.  First trimester serum screening for down's syndrome , 1995, Prenatal diagnosis.

[22]  J. Moutquin,et al.  Screening for Down syndrome during the first and second trimesters: impact of risk estimation parameters. , 1995, Clinical biochemistry.

[23]  J. Canick,et al.  Risk‐based prenatal screening for trisomy 18 using alpha‐fetoprotein, unconjugated oestriol and human chorionic gonadotropin , 1995, Prenatal diagnosis.

[24]  A. D'Agata,et al.  Maternal serum screening for Down's syndrome in the first trimester of pregnancy , 1995, British journal of obstetrics and gynaecology.

[25]  M. Brizot,et al.  Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy , 1995, British journal of obstetrics and gynaecology.

[26]  K. Nicolaides,et al.  Maternal Serum Pregnancy-Associated Plasma Protein a and Fetal Nuchal Translucency Thickness for the Prediction of Fetal Trisomies in Early Pregnancy , 1994, Obstetrics and gynecology.

[27]  J. Grudzinskas,et al.  Serum PAPP‐A and free β‐hCG are first‐trimester screening markers for down syndrome , 1994 .

[28]  K. Spencer,et al.  First Trimester Biochemical Screening for Trisomy 21: The Role of Free Beta hCG, Alpha Fetoprotein and Pregnancy Associated Plasma Protein A , 1994, Annals of clinical biochemistry.

[29]  N. Wald,et al.  Four‐marker serum screening for Down's syndrome , 1994, Prenatal diagnosis.

[30]  C. Oxvig,et al.  Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger ribonucleic acid in placenta. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[31]  J. Grudzinskas,et al.  Maternal serum human chorionic gonadotrophin and pregnancy‐associated plasma protein a, markers for fetal down syndrome at 8–14 weeks , 1994, Prenatal diagnosis.

[32]  N. Wald,et al.  First trimester biochemical screening for Down's syndrome. , 1994, Annals of medicine.

[33]  A. Mcguire,et al.  Antenatal Screening for Down's Syndrome , 1997, Journal of medical screening.

[34]  J. Grudzinskas,et al.  Serum PAPP‐A measurements in first‐trimester screening for Down syndrome , 1993, Prenatal diagnosis.

[35]  K. Spencer,et al.  First‐trimester biochemical screening for fetal chromosome abnormalities and neural tube defects , 1993, Prenatal diagnosis.

[36]  J. Grudzinskas,et al.  Serum PAPP‐A levels are depressed in women with fetal Down syndrome in early pregnancy , 1993, Prenatal diagnosis.

[37]  K. Spencer,et al.  First‐trimester free beta (hCG) screening for Down syndrome , 1993, Prenatal diagnosis.

[38]  B. Crandall,et al.  Supported in part by grant No. HD04612 to the Mental Retardation Research Center. Presented at the Fifty-ninth Annual Meeting of the Pacific Coast Obstetrical and Gynecological Society, Ojai, California, October 1118, 1992. , 1993 .

[39]  T. Chard,et al.  Low maternal serum levels of pregnancy associated plasma protein A (PAPP‐A) in the first trimester in association with abnormal fetal karyotype , 1993, British journal of obstetrics and gynaecology.

[40]  J. Haddow,et al.  Pregnancy associated plasma protein A as a marker for Down syndrome in the second trimester of pregnancy , 1993, Prenatal diagnosis.

[41]  L. Cole,et al.  The deactivation of hCG by nicking and dissociation. , 1993, The Journal of clinical endocrinology and metabolism.

[42]  J. Canick,et al.  Multiple-marker screening in pregnancies with hydropic and nonhydropic Turner syndrome. , 1992, American journal of obstetrics and gynecology.

[43]  J. Grudzinskas,et al.  First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome. , 1992, BMJ.

[44]  K. Spencer,et al.  Free β-hCG as first-trimester marker for fetal trisomy , 1992, The Lancet.

[45]  J. M. M. Lith.  First-trimester maternal serum human chorionic gonadotrophin as a marker for fetal chromosomal disorders , 1992 .

[46]  H. Cuckle,et al.  Low maternal serum human chorionic gonadotrophin and unconjugated oestriol in a triploidy pregnancy , 1992, Prenatal diagnosis.

[47]  Howard Cuckle.  Aneuploidy indices in biochemical screening , 1992, Prenatal diagnosis.

[48]  B. No̸rgaard-Pedersen,et al.  CA‐125 as a maternal serum marker for Down's syndrome in the first and second trimesters , 1992, Prenatal diagnosis.

[49]  Robert N. Taylor,et al.  First‐trimester aneuploidy screening using serum human chorionic gonadotropin (hCG), free ahCG, and progesterone , 1991, Prenatal diagnosis.

[50]  L. Cole,et al.  The heterogeneity of human chorionic gonadotropin (hCG). III. The occurrence and biological and immunological activities of nicked hCG. , 1991, Endocrinology.

[51]  L. Jackson,et al.  First‐trimester maternal serum alphafetoprotein and chorionic gonadotropin in aneuploid pregnancies , 1991, Prenatal diagnosis.

[52]  B. Brambati,et al.  Ultrasound and Biochemical Assessment of First Trimester Pregnancy , 1991 .

[53]  R. Osathanondh,et al.  Prenatal screening for trisomy 18 in the second trimester , 1990, Prenatal diagnosis.

[54]  B. Brambati,et al.  Abnormal maternal serum levels of human chorionic gonadotropin free subunits in trisomy 18. , 1990, American journal of medical genetics.

[55]  K. Blakemore,et al.  Evaluation of Evaluations in Maternal Serum Alfa Fetoprotien: A Review , 1990 .

[56]  K. Blakemore,et al.  Evaluation of elevations in maternal serum alpha-fetoprotein: a review. , 1990, Obstetrical & gynecological survey.

[57]  D. Brock,et al.  First‐trimester maternal serum biochemical indicators in Down syndrome , 1990, Prenatal diagnosis.

[58]  I. McFadyen,et al.  Screening for Down's syndrome. , 1988, BMJ.

[59]  J. Canick,et al.  FIRST-TRIMESTER BIOCHEMICAL SCREENING FOR DOWN SYNDROME , 1988, The Lancet.

[60]  R. Frydman,et al.  Physiological Studies of Human Chorionic Gonadotropin (hCG), αhCG, and βhCG as Measured by Specific Monoclonal Immunoradiometric Assays , 1987 .

[61]  B. Brambati,et al.  FETAL CHROMOSOMAL ANEUPLOIDIES AND MATERNAL SERUM ALPHA-FETOPROTEIN LEVELS IN FIRST TRIMESTER , 1986, The Lancet.

[62]  J. Grudzinskas,et al.  Pregnancy-associated plasma protein A: circulating levels during normal pregnancy. , 1981, American journal of obstetrics and gynecology.

[63]  R. Hussa.  Biosynthesis of human chorionic gonadotropin. , 1980, Endocrine reviews.

[64]  S. Halbert,et al.  Antigenic constituents in pregnancy plasma which are undetectable in normal non-pregnant female or male plasma. , 1972, International archives of allergy and applied immunology.